Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers

Description

Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF). Eligibility: Healthy people aged 18 to 55. Design: Participants will be screened. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function. Participants will have 2 inpatient stays at the clinic. Each stay will be for 11 nights, with a 3-week break between. Both DTG and TAF are gel caps swallowed once per day by mouth. Participants will take 1 drug for 8 days during each stay. Participants will have tests to see how their body uses energy: They will spend 23 continuous hours in a special room that measures how much oxygen they breathe in and how much carbon dioxide they breathe out. They will do this a total of 6 times. They will have a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. They will lie on a table. Electrodes will be placed on their hands and feet to measure body fat and lean body mass. They will stand still on a platform for about 30 seconds. High-resolution laser cameras will scan their bodies.

Conditions

Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer Inhibitors

Talk to us

Study Overview

On this page

Study Details

Study overview

Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF). Eligibility: Healthy people aged 18 to 55. Design: Participants will be screened. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function. Participants will have 2 inpatient stays at the clinic. Each stay will be for 11 nights, with a 3-week break between. Both DTG and TAF are gel caps swallowed once per day by mouth. Participants will take 1 drug for 8 days during each stay. Participants will have tests to see how their body uses energy: They will spend 23 continuous hours in a special room that measures how much oxygen they breathe in and how much carbon dioxide they breathe out. They will do this a total of 6 times. They will have a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. They will lie on a table. Electrodes will be placed on their hands and feet to measure body fat and lean body mass. They will stand still on a platform for about 30 seconds. High-resolution laser cameras will scan their bodies.

A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers

Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers

Condition
Healthy Volunteer
Intervention / Treatment

-

Contacts and Locations

Bethesda

National Institutes of Health Clinical Center, Bethesda, Maryland, United States, 20892

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Aged 18 to 55 years.
  • * Able to provide informed consent.
  • * Willing and able to stay in the whole-room indirect calorimetry suite on 6 occasions.
  • * Willing to reside on the metabolic unit in the Clinical Center for 2 stays of 11 consecutive days over the course of 5 weeks.
  • * Willing to allow samples and data to be stored and shared for future research.
  • * Current infection with HIV or hepatitis A, B, or C.
  • * Body mass index (BMI) \<18.5 kg/m\^2 or \>30.0 kg/m\^2.
  • * Weight change \>5% in the past 6 months or a trained athlete.
  • * History of or current cardiovascular disease such as congestive heart failure, heart block, or clinically relevant abnormal ECG as determined by investigators.
  • * History of or current liver disease or alanine transaminase serum level \>2x upper limit of normal.
  • * History of or current kidney disease or renal insufficiency, or estimated creatinine clearance \<=50 mL/min (Modification of Diet in Renal Disease equation).
  • * Current cancer or history of cancer within 5 years of screening, with the exception of squamous cell carcinoma or basal cell carcinoma that is localized and does not require systemic therapy.
  • * History of bariatric surgery.
  • * Diabetes mellitus.
  • * Fasting serum glucose \>126 mg/dL.
  • * History of or current hypo- or hyper-thyroid or abnormal TSH, except minor deviations deemed to be of no clinical significance by the investigator.
  • * History of or current asthma or chronic obstructive pulmonary disease.
  • * History of or current glaucoma.
  • * Psychological conditions by self-report, such as (but not limited to) claustrophobia, clinical depression, bipolar disorders, that would be incompatible with safe and successful participation in this study.
  • * Pregnancy or within 1 year post-partum.
  • * Experiences irregular menstrual cycles.
  • * Breastfeeding.
  • * Blood pressure \>140/90 mm Hg or current antihypertensive therapy.
  • * Anemia, defined as hemoglobin \<13 g/dL (males) or \<12 g/dL (females).
  • * History of illicit drug, opioids, or alcohol abuse within the last 5 years; current use of illicit drugs or opioids (by history) or excessive alcohol (CAGE assessment score \>=2).
  • * Current use of medications/dietary supplements/alternative therapies known to alter energy metabolism.
  • * Current use of prescription medications, including recent use (6 months) of Descovy or Truvada (eg, for purposes of PrEP).
  • * Any history of exposure to cabotegravir (eg, as participant in research study for this drug).
  • * Current use of nonprescriptive medications that may have interactions with study drugs as determined by the investigators.
  • * History of adverse or allergic reactions to the study drugs.
  • * Daily caffeine intake \>500 mg (about 4 cups of coffee)
  • * Current smoker or user of tobacco products.
  • * Participants with dietary allergies, intolerances, or eating patterns that would preclude them from consuming controlled metabolic meals.
  • * Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

National Institute of Allergy and Infectious Diseases (NIAID),

Janaki C Kuruppu, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Allergy and Infectious Diseases (NIAID)

Study Record Dates

2030-01-31